UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):
March 15, 2021

Immunome, Inc.
(Exact name of registrant as specified in its charter)

Delaware	**001-39580**	**77-0694340**
(state or other jurisdiction of incorporation)	**(Commission File Number)**	**(I.R.S. Employer Identification No.)**

665 Stockton Drive, Suite 300	
Exton, Pennsylvania	**19341**
(Address of principal executive offices)	**(Zip Code)**

Registrant's telephone number, including area code: (610) 321-3700

Not applicable
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock, $0.0001 par value per share	**IMNM**	**The Nasdaq Stock Market LLC**

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On or about March 16, 2021, Immunome, Inc. (the "Company") will be posting a presentation to its website that may be used by the Company from time to time with investors, analysts, collaborators, vendors or other third parties. A copy of the presentation is furnished as Exhibit 99.1.

The information in this Item 7.01, including the attached exhibit, is furnished solely pursuant to Item 7.01 of Form 8-K. Consequently, such information is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that section. Further, the information in this Item 7.01, including the exhibit, shall not be deemed to be incorporated by reference into the filings of the registrant under the Securities Act of 1933.

Cautionary Statement Regarding Forward-Looking Information

This current report on Form 8-K contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than those of historical fact in this presentation and accompanying oral commentary are forward-looking statements. Forward-looking statements may be identified by terminology such as "believe," "anticipate," "plan," "may," "intend," "will," "should," "expect," "estimate," "potential" and "continue" and similar expressions, including the negative of these words, but not all forward-looking statements contain these words. Forward-looking statements include, but are not limited to, statements regarding our financial position, strategy, business plans; expectations regarding the timing, progress and achievement of our research and development activities, preclinical studies, any clinical trials and regulatory filings and submissions; our ability to secure and execute on partnerships and collaborations; our expectations regarding the activity and therapeutic potential of our current and future product candidates; our achievement of corporate milestones and the implementation of our business model; and the adequacy of our financial resources to support our operations. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions applicable to Immunome and our industry in general that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, those risks and uncertainties associated with our ability to execute on our strategy, including with respect to the timing of our R&D efforts, regulatory filings, initiation of clinical studies and other anticipated milestones; the timing and effectiveness of any antibody therapeutics which may be developed by us; our ability to finance our operations; the impact of the COVID-19 pandemic on our business, operations, strategy, goals and anticipated milestones; and the additional risks and uncertainties set forth more fully under the caption "Risk Factors" in our final prospectus dated October 1, 2020 and filed pursuant to Rule 424(b) under the Securities Act of 1933 with the United States Securities and Exchange Commission (SEC) and elsewhere in our filings and reports with the SEC. These risks, uncertainties and other factors may cause our actual results to differ materially and adversely from what is contained in (or may be implied from) any forward-looking statements. Forward-looking statements speak as of the date they are made, and the Company undertakes no obligation to update them except as may be required under applicable law.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Presentation dated March 15, 2021 (furnished herewith)
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

IMMUNOME, INC.

By: /s/ Purnanand D. Sarma
Purnanand D. Sarma, Ph.D.
President and Chief Executive Officer

Dated: March 15, 2021

Exhibit 99.1

Harnessing the Human Memory B Cell Response To Develop Antibody-Based Therapeutics

immunome®

March 14, 2021

Immunome, Inc.
665 Stockton Drive, Suite 300
Exton, PA 19341
610.321.3700
www.immunome.com

Forward Looking Statements

This presentation and any accompanying oral commentary contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than those of historical fact in this presentation and accompanying oral commentary are forward-looking statements. Forward-looking statements may be identified by terminology such as "believe," "anticipate," "plan," "may," "intend," "will," "should," "expect," "estimate," "potential" and "continue" and similar expressions, including the negative of these words, but not all forward-looking statements contain these words. Forward-looking statements include, but are not limited to, statements regarding our financial position, strategy, business plans; expectations regarding the timing, progress and achievement of our research and development activities, preclinical studies, any clinical trials and regulatory filings and submissions; our ability to secure and execute on partnerships and collaborations; our expectations regarding the activity and therapeutic potential of our current and future product candidates; our achievement of corporate milestones and the implementation of our business model; and the adequacy of our financial resources to support our operations. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions applicable to Immunome and our industry in general that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, those risks and uncertainties associated with our ability to execute on our strategy, including with respect to the timing of our R&D efforts, regulatory filings, initiation of clinical studies and other anticipated milestones; the timing and effectiveness of any antibody therapeutics which may be developed by us; our ability to finance our operations; the impact of the COVID-19 pandemic on our business, operations, strategy, goals and anticipated milestones; and the additional risks and uncertainties set forth more fully under the caption "Risk Factors" in our final prospectus dated October 1, 2020 and filed pursuant to Rule 424(b) under the Securities Act of 1933, as amended, with the United States Securities and Exchange Commission (SEC) and elsewhere in our filings and reports with the SEC. These risks, uncertainties and other factors may cause our actual results to differ materially and adversely from what is contained in (or may be implied from) any forward-looking statements.

We operate in a quickly evolving industry and it is not possible to predict all risks and uncertainties. Forward-looking statements speak as of the date they are made, and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable law. In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based on information available to us as of the date of this presentation. While we believe that information provides a reasonable basis for these statements, that information may be limited or incomplete. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all relevant information.

In this presentation and oral commentary, we may discuss our current and potential future product candidates that have not yet been approved for marketing by the U.S. Food and Drug Administration. No representation is made as to the safety or effectiveness of these current or potential future product candidates for the use for which such product candidates are being studied.

This presentation does not constitute an offering of securities of any kind.

Immunome Overview

Harness the Power of the Most Educated Components of the Human Immune System

Proprietary Discovery Engine

- Rapid and unbiased interrogation of human memory B cells to identify novel targets and antibodies directed at them
- Output has potential to advance 1-2 candidates into IND-enabling studies per year
- Broad applicability across therapeutic areas allows for partnering opportunities

Oncology (IMM-ONC-01)

- First-in-class fully human antibody targeting IL-38 protein
- IND filing anticipated in 2H 2021
- Growing portfolio of over 50 novel antibody-target pairs for additional therapeutic candidates

Infectious Diseases (IMM-BCP-01)

- COVID-19 Multi-Antibody Cocktail targeting SARS-CoV-2
- IND filing anticipated in 1H 2021
- $13.3M contract from U.S. Department of Defense to fund IMM-BCP-01 research and development
- Rapid B cell interrogation potentially enables rapid response to future infectious disease threats

The Power of Memory B Cells

Immunome's Discovery Engine Sees Disease Through the Lens of the Human Memory B Cell

Memory B cells are the most educated component of the immune response

- Memory B cells remember specific antigens and allow for a rapid antibody response[1]
- The antibodies that these cells produce are a primary component of the body's response to a number of diseases:
  - In cancer, the presence of memory B cells in tumors is associated with favorable outcomes in response to I/O therapy[2-4]
  - In infectious disease, these cells produce the high affinity antibodies that are responsible for fighting disease



1. B Cell Localization and Migration in Health and Disease, Arja E. Hauser, Ute E. Höpken, in Molecular Biology of B Cells (Second Edition), 2015
2. Helmink et al Nature 577, 549-555; 2020
3. Petitprez et al Nature 577, 556-560; 2020
4. Cabrita et al Nature 577 ,561-565; 2020

Immunome Discovery Engine

Unbiased Interrogation of Memory B Cells Yields a Deep and Diverse Set of Potential Therapies



Patient Sampling
Ongoing access to new and diverse patient memory B cells to feed the engine

Patient Response
Capture memory B cells from cancer or infectious disease patients

Antibody Screening
Deep, multiplexed interrogation of patient memory B cell responses

Antibody Validation
Definitive target identification and characterization of antibody / target interactions

Discovery Engine Output
Unique therapeutic antibody / antigen target pairs

Immunome Discovery Engine Differentiators

- Primary human memory B cells immortalized as stable hybridomas - **thousands** of hybridomas per patient
- High-throughput screening - **20,000 antibodies per array**
- Deep **interrogation of patient response** to generate "hits," high conversion rate from hits to targets
- Directly isolates **potential therapeutic antibodies** for use in oncology and infectious diseases

Immunome Pipeline & Anticipated Milestones

Oncology	Target	Product Candidate Description	Discovery	Preclinical	Next Milestone
IMM-ONC-01	IL-38	I/O, Novel Checkpoint			Anticipate IND filing 2H 2021

Anti-infectives	Target	Product Candidate Description	Discovery	Preclinical	Next Milestone
IMM-BCP-01	Multiple SARS-CoV-2 proteins	Antibody cocktail			Anticipate IND filing 1H 2021


immunome
Oncology

Untapped Potential in Immuno-Oncology

Current Therapies are Based on Limited Understanding of the Diversity and Complexity of Human Tumors

T cell targeted immuno-oncology approaches have redefined the way we treat cancer

However, large number of patients cannot be treated using T cell-targeted approaches

Tumors subvert immunity through multiple mechanisms, often simultaneously[1]

T cell compartment is only one component of a complex immune response to tumors

---

B cells offers untapped biology and a new approach to advancing a novel wave of targets and therapies



1. Bonaventure et al 2019 Front Immunol doi:10.3389/fimmu.2019.00168

Immunome's Discovery & Output

Memory B Cell Interrogation Reveals Target "Clusters"

Provides critical insights into cancer biology such as:

- Common biological processes that may have disease relevance, such as exosome control of the tumor microenvironment[1-2]
- Novel immune checkpoints that serve as functional, tumor-derived inhibitors of immunity

A Highly Productive Platform; Outputs To Date:

300,000 hybridomas | 1,300 hits

50+ antibody / antigen pairs[3]

1. Adv Clin Chem. 2016;74:103-41.DOI: 10.1016/bs.acc.2015.12.005
2. Mol Cancer. 2019 Oct 25;18(1):146. doi:10.1186/s12943-019-1074-3
3. Including some commercially-validated targets such as ERBB2

IL-38: A Novel Oncology Target

IL-38 Appears to Dampen Anti-Tumor Immunity

Blocking IL-38 is expected to boost anti-tumor immunity

- IL-38 is an IL-1 cytokine family member, but most closely resembles the natural antagonists of the family (IL-1Ra and IL-36a)
- IL-38 inhibits infiltration & pro-inflammatory activity of innate immune cells (e.g., MΦ, γδT cells, DCs)
- IL-38 inhibits innate immune responses by dendritic cell precursors, macrophages

Typical Inflammatory Anti-tumor Response



1.Crystal Structure Research Collaboratory for Structural Bioinformatics Protein Data Bank (rcsb.org) PDB 5BOW

IL-38 Expression in Solid Tumors

TCGA (The Cancer Genome Atlas) Analysis Suggests IL-38 is Expressed Across Multiple Solid Tumor Types



Inverse relationship between IL-38 expression and immune cell infiltration in tumors

- IL-38 expressed at high levels in subsets of biopsies of major solid tumors[1]
- Biopsy material from 400 lung cancer patients revealed association between high IL-38 expression levels and poor patient outcomes[2]

1. Immunome analysis of the Cancer Genome Atlas (TCGA) data from Firehouse Legacy dataset
2. Takeda et al. PLOS ONE 2017 doi.org/10.1371/journal.pone.0181598

Relationship with Patient Outcomes

IL-38 Levels Correlate with Poor Patient Outcomes

Low IL-38 correlates with **longer disease-free & overall survival** in lung adenocarcinoma patients





High IL-38 expression correlates with **PD-L1 positive** cases in lung cancer



1.Takeda et al. PLOS ONE 2017 doi.org/10.1371/journal.pone.0181598

IL-38 and Innate Immunity

IL-38 Inhibits Myeloid Cell Activation *In Vitro*

Blocks IL-36 mediated inflammatory signals



IL-36γ induced IL-8 in PBMCs
PNAS 2012;109(8):3001

Suppresses Dendritic Cell Function



Reduction of DC Stimulatory Capacity
J. Cell Mol. Med. 2020;24(1):371

Inhibits macrophage inflammatory response



LPS induced RNA expression in THP-1
Immunome Data

IL-38 Antibody
In Vivo Efficacy

IMM-ONC-01 Inhibits Tumor Growth in Animal Model



- B16 F10 mouse melanoma model: immunologically cold
- Expresses IL-38: Immune-suppressive tumor microenvironment
- Mouse CTLA4 inhibitor: relevant I/O control for this model

IMM-ONC-01 is a first-in-class, fully-human antibody candidate targeting IL-38

- IL-38 regulates adaptive and innate immunity by binding receptors found on immune cell subsets
- IL-38 is highly expressed in multiple human solid tumors
- Modulation of IL-38 levels in mouse models correlates with immune responsiveness, tumor growth
- Immunome's anti-IL-38 antibody candidate binds and antagonizes IL-38 activity *in vitro* and demonstrates efficacy in mouse syngeneic tumor models
- Potential indications include multiple cancers with high unmet medical need, both as single-agent and in combination with standards of care including PD1-axis
- **IMM-ONC-01 IND filing anticipated in 2H 2021**



huIgG (PDB 1HZH)[1]

1.Crystal Structure: Research Collaboratory for Structural Bioinformatics Protein Data Bank (rcsb.org): PDB 1HZH


immunome
Infectious Diseases

IMM-BCP-01 | Therapeutic Antibody Cocktail Against Multiple SARS-CoV-2 Antigens

Discovery engine enables rapid isolation of antibodies against SARS-CoV-2 and potentially other infectious agents

Select convalescent patients with strong anti-viral titer	Deep repertoire screening against multiple viral proteins	Antibody cocktail for potential prophylaxis and treatment
Collect blood and isolate memory B cells from super responders 	 Screen for anti-viral antibodies	Produce antibody mixture (up to 6 Abs) using recombinant manufacture 

immunome

Collaboration with U.S. DoD awarded, up to $13.3M in funding

IMM-BCP-01 Hypothesis

Other Single Neutralizing Antibody Therapeutics vs. Immunome's Antibody Cocktail Approach

Single Neutralizing Antibody

- Targets single protein
- New strains may readily evade



IMM-BCP-01

- Targets multiple viral proteins
- Broader coverage across multiple variants



IMM-BCP-01 Profile

- Multiple antibodies against diverse viral antigens
- Approach can be exploited as a rapid response platform for use against other emerging infections

B Cell Interrogation of Super-Responders

Anti-SARS-CoV-2 Antibodies from "Super Responders"

More than 50%
of the antibodies identified
bind
to SARS-CoV-2 proteins
other than Spike





- Open Reading Frame-coded (ORF) proteins and nucleocapsid represent the most prevalent non-spike targets
- Antibody response to neutralizing and non-neutralizing epitopes on spike protein are committed to B cell memory
- Response appears to extend beyond Immunoglobulin G (IgG), comprising of affinity-matured antibodies with specialized function (IgA and IgM)

https://www.biorxiv.org/content/10.1101/2021.01.27.426534v1.

Anti-Spike Antibodies

Super Responders Express Broadly Neutralizing Antibodies, Including Those Binding to Conserved Epitopes of SARS-CoV-1 and SARS-CoV-2

SARS-CoV2 super responders mount a robust immune response

- Antibodies identified against non-overlapping regions of SARS-CoV-2 spike protein, including those regions containing critical mutational variants
- Certain antibodies also neutralize pseudoviruses expressing the spike protein of the South African Variant (B.1.351)
- Our discovery engine has identified antibodies that bind to conserved epitopes of SARS-CoV-1 and SARS-CoV-2 spike



IMM-BCP-01: potential as therapy and prophylaxis for SARS-CoV-2

- Immunome data confirm that patients mount immune response against multiple SARS-CoV-2 antigens
- IMM-BCP-01 antibody selection is currently underway
- Anti-Spike antibodies demonstrate capability of neutralizing multiple SARS-CoV-2 variants
- Contract Development and Manufacturing Organization has been selected
- **Planned IND filing in H1 2021**


immunome
Summary

Immunome Pipeline & Anticipated Milestones

Oncology	Target	Product Candidate Description	Discovery	Preclinical	Next Milestone
IMM-ONC-01	IL-38	I/O, Novel Checkpoint			Anticipate IND filing 2H 2021

Anti-infectives	Target	Product Candidate Description	Discovery	Preclinical	Next Milestone
IMM-BCP-01	Multiple SARS-CoV-2 proteins	Antibody cocktail			Anticipate IND filing 1H 2021

- Proprietary Discovery Engine enables the interrogation of human memory B cells to simultaneously identify potential first-in-class antibody therapeutics and novel antigen targets
  - Unbiased, broad, deep and fast
- Two lead preclinical programs in oncology and infectious disease, with INDs expected in 2021
  - IMM-ONC-01: First-in-class fully-humanized anti-IL38 antibody
  - IMM-BCP-01: Antibody cocktail against diverse SARS-CoV-2 antigens
- The Discovery Engine efficiency potentially allows 1-2 programs IND-enabling studies per year
  - Over 1,300 oncology hits; 50+ targets
  - Significant potential as a rapid response platform against future infectious agents


immunome
Appendix

Management Team

Leadership with experience in the fields of oncology, infectious disease, drug discovery and leveraging platform technologies for drug development

Purnanand Sarma, PhD
President & CEO
Former CEO, TARIS Biomedical; VP & GM, Cephalon; VP & Managing Director, Nektar Therapeutics

Michael Morin, PhD
Chief Science Officer
Oversaw cancer, immunology and anti-bacterial drug discovery

Diane Marcou
Chief Financial Officer

Sandra Stoneman, Esq.
Chief Legal Officer

Matthew Robinson, PhD
SVP, Research & Development

Fang Shen, PhD
VP, Research & Translational Biology

Dennis Dong, PhD
VP, Product Development

Pavel Nikitin, PhD
Director, Antibody Engineering

Jillian DiMuzio
Senior Director, HTS & Automation

Ben Harman, PhD
Director, Target Identification

Lifang Liang, PhD
Head of Anti-Infectives & Government Liaison

Scientific Advisory Board

Oncology

Scott Dessain, MD, PhD
Chair, Founder
Joseph and Ray Gordon Chair of Clinical Oncology and Research at Lankenau Institute for Medical Research

George Prendergast, PhD
Cancer Biology
Former Editor of Cancer Research
President and CEO of Lankenau Institute for Medical Research

William Strohl, PhD
Antibody Engineering & GMP
Formerly Centocor, Biologics Lead at J&J

Anthony Tolcher, MD, FRCPC
Early Clinical Development
NEXT Oncology, San Antonio Medical Center

Louis Weiner, MD
Immuno-Oncology
Director, Georgetown Lombardi Comprehensive Cancer Center and Director, MedStar Georgetown Cancer Institute

COVID-19

Michael Diamond, MD, PhD
Washington University School of Medicine
The Herbert S. Gasser Professor of Medicine and Professor of Molecular Biology Pathology and Immunology
Associate Director, for the Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy Programs

Jeffery Henderson, MD, PhD
Washington University
Associate Professor of Medicine and Molecular Biology
Member, National Convalescent Plasma Project (CCPP19)

Shmuel Shoham, MD
Johns Hopkins University School of Medicine
Associate Professor of Medicine
Member, National Convalescent Plasma Project (CCPP19)

Susan Weis, PhD
University of Pennsylvania Perelman School of Medicine
Professor and Vice Chair, Department of Microbiology
Co-Director, Penn Center for Research on Coronaviruses and Other Emerging Pathogens

Board of Directors

Michael Rapp
Managing Partner, Broadband Capital Investments, LLC

Richard Baron
Formerly Chief Financial Officer, Zynerba Pharmaceuticals

John LaMattina, PhD
Formerly President, Pfizer Global Research & Development

Michael Lefenfeld
President and CEO, Cyanco International
Co-founder of SiGNa Chemistry

Purnanand Sarma, PhD
President & CEO, Immunome Inc.

Philip Wagenheim
Managing Partner, Broadband Capital Partners, LLC

Michael Widlitz, MD
Formerly of clinical development & medical affairs at Pfizer


immunome
665 Stockton Drive, Suite 300
Exton, PA 19341
610.321.3700
www.immunome.com